Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements

Journal:

Expert Rev Cardiovasc Ther

First published: July 28, 2022 DOI: 10.1080/14779072.2022.2103541

Abstract

Vital parameters:	BP 144/87 mm Hg Low-density lipoprotein cholesterol (LDL-C) 112 mg/dL High-density lipoprotein cholesterol (HDL-C) of 47 mg/dL Triglycerides 190 mg/dL (-) tobacco, (-) alcohol Body mass index (BMI) 33 kg/m²
Medication:	Valsartan 80 mg/d
Family history:	Father developed type 2 diabetes mellitus (T2DM) and ASCVD at age 58
Labs:	Fasting blood glucose 103 mg/dL HbA1C 5.8% Serum Creatinine 1.1 mg/dL Urinary analysis within normal limits